<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Phase I trial &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/phase-i-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 18:11:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Phase I trial &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>NK Cell Infusion Shows Promise in Liver Cancer Trial</title>
		<link>https://bioengineer.org/nk-cell-infusion-shows-promise-in-liver-cancer-trial/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 18:10:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[**Uygun Etiketler:** Hepatocellular carcinoma]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[liver transplantation]]></category>
		<category><![CDATA[Liver transplantation recurrence]]></category>
		<category><![CDATA[NK cell therapy]]></category>
		<category><![CDATA[Phase I trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nk-cell-infusion-shows-promise-in-liver-cancer-trial/</guid>

					<description><![CDATA[In a remarkable advancement in the field of oncology, particularly in the treatment of hepatocellular carcinoma (HCC), recent research has shed light on the potential of Natural Killer (NK) cell infusion therapy for patients who have faced recurrent cancers post-liver transplantation. This groundbreaking phase I trial, led by researchers including Yang, F., Gong, Y., and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320397</post-id>	</item>
	</channel>
</rss>
